wiki pageCreated: 2026-04-02T07:18:59By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-therapeutics-sodium-selenate
📖 Wiki Page
therapeutic1038 wordssynced 2026-04-02
Sodium Selenate
Introduction
Sodium selenate is an inorganic selenite compound that has emerged as a promising disease-modifying therapeutic for tauopathies, including [Alzheimer's disease](/diseases/alzheimers-disease), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear- palsy) (PSP), and [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS). The compound works primarily by activating [Protein Phosphatase 2A](/proteins/pp2a) (PP2A), the major serine/threonine phosphatase responsible for dephosphorylating [tau protein](/proteins/tau) in the brain[@van2010](https://doi.org/10.1186/1750-1326-5-8).
Sodium selenate is an inorganic selenite compound that has emerged as a promising disease-modifying therapeutic for tauopathies, including [Alzheimer's disease](/diseases/alzheimers-disease), [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear- palsy) (PSP), and [Corticobasal Syndrome](/diseases/corticobasal-syndrome) (CBS). The compound works primarily by activating [Protein Phosphatase 2A](/proteins/pp2a) (PP2A), the major serine/threonine phosphatase responsible for dephosphorylating [tau protein](/proteins/tau) in the brain[@van2010](https://doi.org/10.1186/1750-1326-5-8).
Sodium selenate's primary mechanism involves the activation of PP2A, which is the predominant phosphatase responsible for removing phosphate groups from tau at pathologically relevant sites. In [Alzheimer's disease](/diseases/alzheimers-disease) and related tauopathies, PP2A activity is reduced by approximately 50%, contributing to tau hyperphosphorylation and neurofibrillary tangle formation[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015).
The compound promotes PP2A activation through multiple pathways:
Stabilization of PP2A holoenzyme: Sodium selenate promotes the assembly and stabilization of the PP2A-B55α holoenzyme, the specific form responsible for tau dephosphorylation in the brain[@van2010](https://doi.org/10.1186/1750-1326-5-8)
Enhancement of methylation: The compound increases Leu309 methylation of the PP2A catalytic subunit, which is essential for B55α regulatory subunit recruitment and holoenzyme assembly[@kremer2011](https://doi.org/10.1016/j.neurobiolaging.2010.08.016)
Reduction of endogenous inhibitors: Sodium selenate reduces the activity of endogenous PP2A inhibitors such as SET/I2PP2A and CIP2A, which are elevated in AD brain[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015)
Tau Dephosphorylation
By activating PP2A, sodium selenate facilitates the dephosphorylation of tau at multiple pathologically relevant sites:
Thr181 (AT270 epitope; p-tau181 biomarker)
Ser202/Thr205 (AT8 epitope; most widely used marker for tau pathology)
This broad dephosphorylation profile distinguishes sodium selenate from kinase inhibitors that typically target individual phosphorylation enzymes[@van2010](https://doi.org/10.1186/1750-1326-5-8).
Preclinical Evidence
Animal Model Studies
Multiple preclinical studies have demonstrated sodium selenate's efficacy in tauopathy models:
3xTg-AD mice: Sodium selenate treatment reduced tau hyperphosphorylation in the hippocampus and cortex, with improvements in cognitive performance on behavioral tests[@van2010](https://doi.org/10.1186/1750-1326-5-8)
P301L tau transgenic mice: Treatment with sodium selenate reduced tau pathology and improved synaptic function[@sanchezarias2019](https://doi.org/10.1016/j.nbd.2019.01.017)
Mechanism validation: Studies confirmed that the anti-tau effects were PP2A-dependent, as PP2A inhibitors blocked the therapeutic benefit[@van2010](https://doi.org/10.1186/1750-1326-5-8)
Bioavailability Challenges
A significant challenge in sodium selenate development has been achieving sufficient brain penetration. Early formulations had limited central nervous system exposure, necessitating high doses that increased the risk of off-target effects. Development programs have focused on improving brain penetration through optimized formulations[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976).
Clinical Development
VEL015 Phase IIa Trial (Alzheimer's Disease)
The most advanced clinical program (VEL015) evaluated sodium selenate in mild-to-moderate Alzheimer's disease:
Phase IIa results: The trial demonstrated safety and tolerability with biomarker trends suggesting disease modification[@kremer2011](https://doi.org/10.1016/j.neurobiolaging.2010.08.016)
Primary endpoints: The study met its safety objectives, with trends toward biomarker improvement in cerebrospinal fluid tau levels[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976)
Status: Further clinical development has continued with a focus on optimizing dosing and formulation
PSP Clinical Trials
Sodium selenate has been specifically studied in PSP, a 4R-tauopathy where PP2A dysfunction contributes to the characteristic tau pathology:
Rationale: PSP involves predominant 4R-tau aggregation, and PP2A activity is reduced in basal ganglia and brainstem regions affected in PSP[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015)
Clinical trials: Several Phase 1/2 trials evaluated sodium selenate in PSP patients, with mixed results regarding efficacy[@wang2014](https://doi.org/10.1002/mds.25639)
Outcome: The PSP trials demonstrated safety but showed limited efficacy in clinical endpoints, leading to reevaluation of the therapeutic approach
Adversarial Information
Negative Trial Results
The clinical development of sodium selenate has faced significant challenges:
Limited brain penetration: Early formulations did not achieve sufficient CNS exposure, potentially limiting therapeutic efficacy[@giacomini2022](https://doi.org/10.3389/fnins.2022.1058976)
Modest efficacy signals: Clinical trials in both AD and PSP showed biomarker trends but did not meet primary clinical endpoints[@kremer2011](https://doi.org/10.1016/j.neurobiolaging.2010.08.016)
Formulation challenges: The requirement for intravenous administration limits convenience and long-term use
Concerns and Limitations
Narrow therapeutic window: Selenium compounds can be toxic at higher doses, necessitating careful dose selection[@wang2014](https://doi.org/10.1002/mds.25639)
Mechanism questions: Whether PP2A activation alone is sufficient to modify disease progression remains uncertain
Competition: Other PP2A-targeting approaches (FTY720/fingolimod, SET inhibitors) are in development and may offer advantages[@hernandez2013](https://doi.org/10.1016/j.neuropharm.2012.08.015)
Why Trials May Have Failed
Several factors may explain the limited clinical success:
Insufficient target engagement: Brain concentrations may have been inadequate to fully activate PP2A
Disease stage: Patients enrolled may have had too advanced disease for meaningful intervention
Biomarker disconnect: Changes in CSF biomarkers may not translate to clinical benefit
Complexity of PP2A regulation: Global PP2A activation may have unintended effects on other substrates
Current Status and Future Directions
Ongoing Development
Formulation optimization: New oral formulations with improved brain penetration are in development
Combination approaches: Combining sodium selenate with other disease-modifying agents is being explored
Biomarker-driven patient selection: Future trials may enrich for patients with biomarkers indicating PP2A dysfunction
[PP2A Therapeutic Approaches](/proteins/pp2a#therapeutic-approaches) — Related therapies
References
[van Eersel J, Ke YD, Liu X, et al, Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models (2010)](https://doi.org/10.1186/1750-1326-5-8)
[Hernandez F, Avila J, Andres-Benito P, et al, Protein phosphatase 2A and Alzheimer's disease (2013)](https://doi.org/10.1016/j.neuropharm.2012.08.015)
[Kremer GP, van Eersel J, Lardelli I, et al, PP2A activation as a therapeutic strategy in Alzheimer's disease (2011)](https://doi.org/10.1016/j.neurobiolaging.2010.08.016)
[Sanchez-Arias JA, Santos-Galindo M, Izcoa A, et al, PP2A activation in tauopathy models (2019)](https://doi.org/10.1016/j.nbd.2019.01.017)
[Giacomini A, Tagliavini F, Bolognin S, CNS drug development for Alzheimer's disease: current status and future perspectives (2022)](https://doi.org/10.3389/fnins.2022.1058976)
[Wang X, Sun G, Feng T, et al, PP2A in Parkinson's disease and related neurodegenerative disorders (2014)](https://doi.org/10.1002/mds.25639)